Table 3. Drug toxicity mechanism and timing for Tubular and Nephrolithiasis phenotypes.
Drug | Tubular | Nephrolithiasis | Time Course | Genetic Mechanism | ||
---|---|---|---|---|---|---|
Type A | Type B | Type A | Type B | |||
Acyclovir | X | SA | OAT | |||
Atazanavir | X | SA | ||||
Cisplatin | X | SA/Chronic | OAT | |||
Didanosine | X | SA | OAT/Mitochondria | |||
Foscarnet | X | SA | NaPO4 transport | |||
Ifosfamide | X | SA/Chronic | OAT | |||
Indinavir | X | SA | OCT | |||
Lamivudine | X | SA | OAT | |||
Lithium | X | SA/Chronic | VA receptors | |||
Ritonavir | X | SA | MRP 2,4 PGP | |||
Tenofovir | X | SA | OAT |
Type A= dose dependent toxicity, Type B= idiosyncratic, acute = within 7 days of drug initiation, SA = sub-acute, occurs within 4 weeks of drug exposure and may take up to 90 days to resolve, chronic = injury persisting beyond 90 days, OAT=organic anion transporter, HLA = human leukocyte antigen, CYP = cytochrome P450, PGP = p-glycoprotein, MRP = multi-drug resistance associated protein